Other News To Note
Monday, February 14, 2011
Gilead Sciences Inc., of Foster City, Calif., refiled its new drug application (NDA) for the single-tablet regimen of Truvada (emtricitabine and tenofovir disoproxil fumarate) and TMC278 (rilpivirine hydrochloride), a non-nucleoside reverse transcriptase inhibitor from Tibotec Pharmaceuticals Ld., a unit of New Brunswick, N.J.-based Johnson & Johnson.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.